Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth factors and endothelial dysfunction.

C Bauters1, I Six, T Meurice

  • 1Cardiology B Department and Pharmacology Laboratory, Lille University Hospital, France.

Drugs
|October 20, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2016
Same author

Autologous Mesenchymal Stem Cells Show More Benefit on Systolic Function Compared to Bone Marrow Mononuclear Cells in a Porcine Model of Chronic Myocardial Infarction.

Journal of cardiovascular translational research·2015
Same author

Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis.

Journal of thrombosis and haemostasis : JTH·2015
Same author

High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Antithrombotic therapy in diabetic patients with coronary artery disease.

Panminerva medica·2015
Same author

The onset of left ventricular diastolic dysfunction in SHR rats is not related to hypertrophy or hypertension.

American journal of physiology. Heart and circulatory physiology·2012
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Endothelial dysfunction contributes to cardiovascular diseases. Growth factors like basic FGF (fibroblast growth factor) and VEGF (vascular endothelial growth factor) show promise in treating vascular diseases by improving endothelial function.

Area of Science:

  • Cardiovascular Research
  • Cell Biology
  • Regenerative Medicine

Background:

  • Endothelial dysfunction is central to cardiovascular diseases, affecting vasomotion, thrombosis, and neointimal proliferation.
  • It is a hallmark of atherosclerotic vessels, mechanically injured sites, and collateral vessels in ischemia.
  • Endothelial cells rely on growth factors like FGF and VEGF in vitro.

Purpose of the Study:

  • To investigate the therapeutic potential of endothelial cell growth factors in vivo.
  • To explore the role of basic FGF (bFGF) and VEGF in improving endothelial dysfunction.
  • To assess the impact of these factors on vascular repair and function.

Main Methods:

  • Administration of basic FGF and VEGF in animal models of endothelial dysfunction.

Related Experiment Videos

  • Evaluation of collateral vessel development in ischemic models.
  • Assessment of endothelial regrowth after arterial injury.
  • Analysis of experimental atherosclerosis models.

    • Main Results:

    • In vivo administration of bFGF and VEGF enhanced collateral vessel formation in ischemia.
    • These growth factors promoted endothelial regrowth following arterial injury.
    • Significant improvements in endothelium-dependent responses were observed in various animal models.
    • Beneficial effects were noted in collateral circulation, regenerated endothelium, and experimental atherosclerosis.

    Conclusions:

    • Endothelial cell growth factors, including bFGF and VEGF, demonstrate therapeutic potential for vascular diseases.
    • These factors improve endothelium-dependent responses and vascular repair mechanisms.
    • Further research into the precise mechanisms is warranted, but these findings support their use in clinical settings for vascular conditions.